Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_4
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Withdrawn2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_4

Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881
withdrawnphase_3

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

NCT04057261
withdrawnphase_2

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

NCT03371862

Clinical Trials (3)

Showing 3 of 3 trials
NCT03260881Phase 4

Liraglutide Effects on Epicardial Fat Inflammatory Genes

Completed
NCT04057261Phase 3

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Withdrawn
NCT03371862Phase 2

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3